APPealing for a role in cellular iron efflux

DOI 10.1074/jbc.L119.009216

Debomoy K. Lahiri¹, Bryan Maloney, and Ruizhi Wang

From the Department of Psychiatry and of Medical and Molecular Genetics, Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, Indiana 46202

Edited by Ruma Banerjee

Dlouhy *et al.* (1) recently refined how β -amyloid precursor protein (APP)² participates in iron (Fe) efflux and hinted that APP may be unnecessary for ferroportin-supported Fe efflux. APP and Fe efflux have long been our interest, given recent work on the APP mRNA 5'-UTR and how regulation of APP translation operates through an interleukin-1 acute box, an iron response element (IRE), where iron-responsive protein 1 (IRP1) binds, and a target sequence for microRNA-346 (2). Untangling the roles of IRE, IRP1, interleukin-1, and miR-346 at the APP 5'-UTR is critical in Alzheimer's disease (AD). Fe regulation of APP levels through this site is well-documented (3). For example, that APP knockout alters Fe efflux in model mice (4) argues in favor of APP regulation of Fe efflux. Dlouhy's group (1) reported that cellular APP plays no role in Fe homeostasis, at least with ferroportin, and secreted APP (sAPP) stabilizes ferroportin at the cell membrane (5). In normal cells, APP is processed by α - or β -secretase to generate sAPP α or sAPP β , respectively. Post-translational secretase modification of APP alters neuronal Fe homeostasis (6). Because the APP they generated used a C-terminal tag that probably prevented secretase processing, it would have eliminated sAPP. They examined the

² The abbreviations used are: APP, β-amyloid precursor protein; sAPP, secreted APP; IRE, iron response element; AD, Alzheimer's disease.

specific form of APP that was not implicated in Fe metabolism in their own previous work (5) and suitably found further lack of implication. Nevertheless, their work of APP on Fe efflux will encourage researchers to examine effects of more AD relevance, such as the sAPP α (nonamyloidogenic pathway) *versus* sAPP β (amyloidogenic pathway), and cytokines and microRNA regulation of APP in overall Fe metabolism as well as AD pathogenesis, progression, and therapeutics.

References

- Dlouhy, A. C., Bailey, D. K., Steimle, B. L., Parker, H. V., and Kosman, D. J. (2019) Fluorescence resonance energy transfer links membrane ferroportin, hephaestin but not ferroportin, amyloid precursor protein complex with iron efflux. *J. Biol. Chem.* 294, 4202–4214 CrossRef Medline
- Long, J. M., Maloney, B., Rogers, J. T., and Lahiri, D. K. (2019) Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: implications in Alzheimer's disease. *Mol. Psychiatry* 24, 345–363 CrossRef Medline
- Bandyopadhyay, S., Cahill, C., Balleidier, A., Huang, C., Lahiri, D. K., Huang, X., and Rogers, J. T. (2013) Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for Down syndrome and Alzheimer's disease. *PLoS One* 8, e65978 CrossRef Medline
- Belaidi, A. A., Gunn, A. P., Wong, B. X., Ayton, S., Appukuttan, A. T., Roberts, B. R., Duce, J. A., and Bush, A. I. (2018) Marked age-related changes in brain iron homeostasis in amyloid protein precursor knockout Mice. *Neurotherapeutics* 15, 1055–1062 CrossRef Medline
- McCarthy, R. C., Park, Y. H., and Kosman, D. J. (2014) sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. *EMBO Rep.* 15, 809–815 CrossRef Medline
- Tsatsanis, A., Dickens, S., Kwok, J. C. F., Wong, B. X., and Duce, J. A. (2019) Post Translational Modulation of beta-Amyloid Precursor Protein Trafficking to the Cell Surface Alters Neuronal Iron Homeostasis. *Neurochem. Res.* 44, 1367–1374 CrossRef Medline

This work was supported by grants from the US National Institutes of Health: R01AG051086, R01MH106568, R01DA044242, and P30AG010133. The authors declare that they have no conflicts of interest with the contents of this article.

¹ To whom correspondence should be addressed: Dept. of Psychiatry, Neuroscience Research Center, Indiana University School of Medicine, 320 W. 15th St., Indianapolis, IN 46202. Tel.: 317-274-2706; E-mail: dlahiri@ iupui.edu.